𝔖 Bobbio Scriptorium

✦ LIBER ✦

Editorial Comment on: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

✍ Scribed by Mark J. Speakman

Book ID: 113610695
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 79 KB
Volume: 54
Category: Article
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2008.03.071

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Editorial Comment on: Placebo-Controlled

Editorial Comment on: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

✍ Vincenzo Ficarra; Giacomo Novara 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Editorial Comment on: Placebo-Controlled

Editorial Comment on: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

✍ Patrick J. Bastian 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Placebo-Controlled Dose-Ranging Phase 2

Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

✍ Frans Debruyne; Arkadij A. Gres; Dmitrii L. Arustamov 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 561 KB

Placebo-Controlled Dose-Ranging Phase 2

Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

✍ Roehrborn, C.G. 📂 Article 📅 2008 🏛 Elsevier Science ⚖ 54 KB

Re: Frans Debruyne, Arkadij A. Gres, Dmi

Re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia. Eur Urol 2008;54:170–80

✍ Tomasz Drewa; Piotr Chlosta 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Reply to Tomasz Drewa and Piotr Chlosta'

Reply to Tomasz Drewa and Piotr Chlosta's Letter to the Editor re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia. Eur Urol 2008;54:170–80

✍ Frans Debruyne; Arkadij A. Gres; Dmitrii L. Arustamov 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 70 KB